Navigation Links
Mayo collaboration finds source of breast drug side effect
Date:9/27/2010

ROCHESTER, Minn. -- Mayo Clinic researchers and their international colleagues have discovered genetic variants that lead to severe arthritis for a subset of women when taking aromatase inhibitors to treat their breast cancer. This serious side effect is so painful that many women halt their lifesaving medication. The findings appear today in the online issue of Journal of Clinical Oncology.

"Many women stop taking aromatase inhibitors due to the accompanying joint pain," says James Ingle, M.D., Mayo Clinic oncologist and senior author of the study. "We used the latest genetic technology in a very large group of women and discovered totally new clues to the cause of the main reason women stop this potentially lifesaving drug. Our findings open the door to finding ways to identify women who will develop these side effects and treat those who do, thus allowing more women to take this therapy and decrease their chances of breast cancer recurrence." Aromatase inhibitors are most often used as adjuvant therapy for postmenopausal women with early stage breast cancer.

How the Research Was Conducted

The researchers -- including investigators from the United States, Canada and Japan -- conducted a genome-wide association study to identify gene variants called single nucleotide polymorphisms (SNPs) that are associated with musculoskeletal pain. They selected patients who were enrolled in a prospective clinical trial, MA27, conducted by the NCIC Clinical Trials Group in Canada in collaboration with the NCI-sponsored North American Breast Cancer Groups comparing two aromatase inhibitor drugs. Two controls were matched with each patient and each patient who was selected experienced arthritis-like side effects within the first two years of treatment, or had already dropped out of the trial because of the pain. Researchers studied 293 separate cases, comparing them to 585 controls.

They found four likely SNPs on chromosome 14
'/>"/>

Contact: Robert Nellis
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Alexza and Biovail Form Collaboration to Develop and Commercialize AZ-004 (Staccato(R) Loxapine) in North America
2. Web Content Management Enables Government Transparency, Participation, and Collaboration Online
3. MedPage Today(R) and Milwaukee Journal Sentinel Develop Journalism Content Collaboration for Enterprise Medical Reporting
4. NIH-FDA Joint Briefing on Regulatory Science Collaboration
5. International Collaboration: FDA and European Medicines Agency Agree to Accept a Single Orphan Drug Designation Annual Report
6. Carefx Delivers Expert Insights on Health Data Sharing, Collaboration, Quality and Meaningful Use
7. Improved doctor-pharmacist collaboration needed: study
8. Tackling cardiovascular disease surge worldwide requires collaboration
9. French-Based Non-Profit AIDES is Starting a New Collaboration With Goodby, Silverstein & Partners
10. European collaboration seeks to create World Wide Web for robots
11. Johns Hopkins School of Medicine enters collaboration with New York Stem Cell Foundation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Dallas, TX (PRWEB) December 19, 2014 ... current state of the global Gliquidone industry with a ... statistics on the market status of the Gliquidone manufacturers ... for companies and individuals interested in the industry. , ... industry including its definition, applications and manufacturing technology. Then, ...
(Date:12/19/2014)... (HealthDay News) -- The tragic death from "rat-bite fever" of ... the pet rodents, according to a report from the U.S. ... a rare but potentially fatal illness that should be considered ... a history of rodent exposure is reported," said a team ... Service. The case outlined in the report occurred in ...
(Date:12/19/2014)... HealthDay Reporter THURSDAY, Dec. 18, 2014 ... for at least 20 seconds you may be at risk ... one leg may indicate that small strokes or tiny bleeds ... strokes is high, the investigators reported online Dec. 18 in ... standing on one leg, as well as problems walking, should ...
(Date:12/17/2014)... HeartMath® Inc., recognized as one ... rate variability (HRV), heart coherence and the physiology ... databases and algorithms to chipset manufacturers and consumer ... partners to offer its HRV solutions, tap into ... as its normative HRV databases and algorithms for ...
(Date:12/17/2014)... Project Veritas is releasing a video ... MIT economist and Obamacare architect Jonathan Gruber to public ... the interview, which is being distributed on YouTube. , ... mislabeling in the Affordable Care Act in order to ... billion dollar per year tax grab. , “President Obama ...
Breaking Medicine News(10 mins):Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 2Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 3Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 4Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 5Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 6Health News:Scratch From Pet Rat Kills Child; CDC Warns of Risk 2Health News:Can You Balance on One Leg? You May Have Lower Stroke Risk 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 3Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2
... BRUNSWICK, N.J. Researchers at Rutgers Ernest Mario School ... the widely used drugs Celebrex (celecoxib, a nonsteroidal anti-inflammatory ... the transition of early prostate cancer to its more ... is the second leading cause of cancer death in ...
... Cancer Center at Thomas Jefferson University in Philadelphia ... pressure medications might help prevent the spread of ... that one type of pressure-lowering drug called an ... and causes cell death. , In earlier work ...
... discovered evidence that a series of genetic mutations work ... often-fatal form of acute lymphoblastic leukemia (ALL). , These ... of a gene, IKZF1, whose protein, Ikaros, normally helps ... a lymphocyte. The researchers also found that loss of ...
... Patented OwnCode(R) Consumer Heart Rate Monitor Technology Now Available in ... ... 2008 Polar, the leader in,heart rate monitoring and fitness ... only available in,Polar heart rate monitors -- can now be ...
... Calif., April 14 HealthFusion, a,national ... recognized for,call center operation customer satisfaction ... Certified Call Center Program(SM). This distinction,acknowledges ... call center,operations to provide "An Outstanding ...
... Galien USA 2008 Announced for September 24, Nominations ... Nobel Laureate Walter,Gilbert, Ph.D., the Carl M. Loeb ... Biogen, has joined fellow Nobel Laureates on the,committee ... research. Prix Galien USA 2008,( http://www.prix-galien-usa.com ) will ...
Cached Medicine News:Health News:Celebrex-Lipitor combo may halt prostate cancer 2Health News:Celebrex-Lipitor combo may halt prostate cancer 3Health News:Blood pressure drugs halt pancreatic cancer cell growth, Jefferson researchers find 2Health News:St. Jude discovery offers new avenues to understanding an aggressive form of leukemia 2Health News:St. Jude discovery offers new avenues to understanding an aggressive form of leukemia 3Health News:Polar Introduces Cost-Effective Solution to Reduce Heart Rate Data Cross-Talk 2Health News:J.D. Power and Associates Reports: HealthFusion Recognized for Providing an Outstanding Customer Service Experience 2Health News:J.D. Power and Associates Reports: HealthFusion Recognized for Providing an Outstanding Customer Service Experience 3Health News:Prix Galien USA Welcomes Eighth Nobel Laureate to its Prestigious Award Committee 2Health News:Prix Galien USA Welcomes Eighth Nobel Laureate to its Prestigious Award Committee 3
(Date:12/19/2014)... Dec. 18, 2014  Sage Analytics ( www.sageanalytics.com ... equipment for the testing of marijuana potency and ... new Luminary™ Profiler, the industry,s first product suite ... a cost-effective, portable unit. Designed from ... of the cannabis industry, the Luminary™ Profiler utilizes ...
(Date:12/19/2014)... , Dec. 18, 2014 Since last ... the site now known as the leading online black ... seen explosive growth in its offering of drugs and ... Alliance show the takedowns did succeed in lowering the ... last review of the markets in August. But some ...
(Date:12/17/2014)... Los beneficios y ganancias están ... de gasto en investigación y desarrollo   ... de septiembre de 2014) ZEISS aumentó sus ingresos en ... (año anterior: 4.190 millones de euros) a pesar de ... crecieron un 14 por ciento, a 360 millones de ...
Breaking Medicine Technology:Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 2Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 3ZEISS confirma su posición en un entorno difícil 2
... Featured Products are kept ... and are offered as ... regular or extra long ... with insulation, flush ports, ...
... Laparoscopic Instruments incorporate a layered design unique ... and monitored to prevent stray electrosurgical burns ... by insulation failure or capacitive coupling; a ... built into all AEM Instruments provides a ...
... AEM Laparoscopic Instruments incorporate a layered design ... shielded and monitored to prevent stray electrosurgical ... caused by insulation failure or capacitive coupling; ... shield built into all AEM Instruments provides ...
... incorporate a layered design unique in the ... to prevent stray electrosurgical burns along the ... failure or capacitive coupling; a well-documented patient ... all AEM Instruments provides a neutral return ...
Medicine Products: